• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Citizens And 2 Other Stocks Under $3 Insiders Are Buying

    4/9/24 9:03:43 AM ET
    $CIA
    $SILO
    Life Insurance
    Finance
    Apparel
    Consumer Discretionary
    Get the next $CIA alert in real time by email

    The Dow Jones index closed lower by around 10 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Citizens

    • The Trade: Citizens, Inc. (NYSE:CIA) Director Terry Sam Maness acquired a total of 1,000 shares an average price of $2.14. To acquire these shares, it cost around $2,137.
    • What’s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.
    • What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.

    Tecogen

    • The Trade: Tecogen Inc. (OTC:TGEN) Director John Hatsopoulos acquired a total of 1,000 shares at at an average price of $0.70. To acquire these shares, it cost around $700.
    • What’s Happening: On March 13, Tecogen reported revenues of $5.9 million and a net loss of $1.8 million for the quarter ended Dec. 31, 2023.
    • What Tecogen Does: Tecogen Inc, designs, manufactures, markets, and maintains high-efficiency, ultra-clean cogeneration products. It operates in three business segments, namely Products, Services, and Energy Production.

    Check This Out: Neogen, Maxeon Solar Technologies And 3 Stocks To Watch Heading Into Tuesday

    Silo Pharma

    • The Trade: Silo Pharma, Inc. (NASDAQ:SILO) CEO and President Eric Weisblum acquired a total of 1,000 shares at an average price of $1.99. The insider spent around $1,988 to buy those shares.
    • What’s Happening: Silo Pharma approved extension of previously announced stock repurchase program authorizing purchase of up to $1 million common stock until April 30.
    • What Silo Pharma Does: SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.

     

    Don’t forget to check out our premarket coverage here

    Get the next $CIA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CIA
    $SILO

    CompanyDatePrice TargetRatingAnalyst
    Citizens Inc.
    $CIA
    7/19/2021$6.70 → $8.40Neutral → Buy
    Goldman Sachs
    More analyst ratings

    $CIA
    $SILO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Silo Pharma Inc.

    SCHEDULE 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

    2/17/26 10:24:44 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Silo Pharma, Inc. (0001514183) (Filer)

    12/29/25 9:04:03 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form EFFECT filed by Silo Pharma Inc.

    EFFECT - Silo Pharma, Inc. (0001514183) (Filer)

    11/28/25 12:15:18 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $CIA
    $SILO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Champion Iron upgraded by Goldman Sachs with a new price target

    Goldman Sachs upgraded Champion Iron from Neutral to Buy and set a new price target of $8.40 from $6.70 previously

    7/19/21 4:47:35 AM ET
    $CIA
    Life Insurance
    Finance

    TD Securities reiterated coverage on Champion Iron Limited (CIA.TO) with a new price target

    TD Securities reiterated coverage of Champion Iron Limited (CIA.TO) with a rating of Buy and set a new price target of $7.00 from $6.50 previously

    1/25/21 2:05:14 PM ET
    $CIA
    Life Insurance
    Finance

    $CIA
    $SILO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Taylor Mary increased direct ownership by 1% to 48,364 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:29:36 AM ET
    $CIA
    Life Insurance
    Finance

    Davis Cynthia H increased direct ownership by 0.93% to 45,967 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:28:28 AM ET
    $CIA
    Life Insurance
    Finance

    Davis Jerry increased direct ownership by 0.99% to 73,165 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:27:24 AM ET
    $CIA
    Life Insurance
    Finance

    $CIA
    $SILO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $CIA
    $SILO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

    SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder (PTSD). The allowed application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," strengthens Silo's growing intellectual-proper

    2/18/26 8:28:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

    Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent ("LOI") with Allucent (US) LLC ("Allucent"), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subject

    12/30/25 8:05:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream

    MIAMI, Dec. 10, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Presenting Day 1 – Today - December 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already regis

    12/10/25 7:00:00 AM ET
    $AEM
    $CIA
    $CLNN
    Precious Metals
    Basic Materials
    Life Insurance
    Finance

    $CIA
    $SILO
    Financials

    Live finance-specific insights

    View All

    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

    Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

    10/6/25 8:10:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $CIA
    $SILO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Silo Pharma Inc.

    SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

    7/26/24 4:17:36 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form SC 13G filed by Silo Pharma Inc.

    SC 13G - Silo Pharma, Inc. (0001514183) (Subject)

    6/13/24 5:08:53 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

    SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)

    1/25/24 5:27:04 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $CIA
    $SILO
    Leadership Updates

    Live Leadership Updates

    View All

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Citizens Appoints Gateway to Lead New Investor Relations Program

    AUSTIN, Texas, March 22, 2022 /PRNewswire/ -- Citizens, Inc. ("Citizens" or the "Company") (NYSE:CIA), has appointed Gateway Group, Inc. ("Gateway"), a leading strategic financial communications and capital markets advisory firm, to manage its new investor relations program. Gateway and Citizens are partnering to create and implement a comprehensive strategic communication and outreach program. The objectives of the new program are to refine Citizens' overall company messaging and corporate positioning, ensure its investment highlights are properly communicated, and to increas

    3/22/22 9:00:00 AM ET
    $CIA
    Life Insurance
    Finance

    Citizens Announces Three New Board Members

    AUSTIN, Texas, Aug. 2, 2021 /PRNewswire/ -- Citizens, Inc. (NYSE:CIA) announces the appointment of three new board members, effective August 1, 2021, demonstrating a continued commitment to Board diversity and an inclusive culture. The new members bring years of insurance experience to the Board, each from a different perspective, bringing unique expertise to enhance the Board's ability to effectively oversee the Company's business operations and guide management's efforts to achieve long-term strategic objectives.  New Board members: Cindy Davis is a seasoned executive in the

    8/2/21 4:12:00 PM ET
    $CIA
    Life Insurance
    Finance